A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors

NCT02667873 | Completed Phase 1

• 1 other identifier: STML-801-0115
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 6

Brief Summary

Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.

Conditions

Solid Tumors

Outcome Measures

Primary Outcomes (2)

• safety and tolerability: percentage of patients experiencing treatment-related and treatment-emergent adverse events

  The percentage of patients experiencing treatment-related and treatment-emergent adverse events

  up to 5 years

• maximum tolerated dose

  To identify the maximum tolerated dose (MTD) of SL-801 or determine the maximum tested dose at which multiple dose-limiting toxicities (DLTs) are not observed.

  up to 5 years

Secondary Outcomes (5)

• Duration of Response

  up to 5 years

• Progression Free Survival

  up to 5 years

• Overall Response Rate

  up to 5 years

• Overall Survival

  up to 5 years

• Pharmacokinetic Profile

  up to 5 years

Study Arms (1)

SL-801

EXPERIMENTAL

The starting dose regimen of SL-801 (that is, the dose regimen in Cohort 1) is 5 milligrams (mg)/day on Days 1-4 and 8-11 every 21 days. In the second portion of the dose escalation stage, participants receive SL-801 orally once daily on days 1-2, 8-9, 15-16 and 22-23 every 28 days. The starting dose will be 70 mg/day (the next planned dose level). The SL-801 dose regimen for a particular participant is dependent on the cohort in which the participant is enrolled.

Drug: SL-801

Interventions

SL-801 DRUG

SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).

Also known as: Felezonexor

SL-801

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The participant must have histologic or cytologic evidence of a malignant solid tumor and must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy likely to result in clinical benefit.
• The participant must have advanced disease, defined as cancer that is either metastatic, or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered feasible).
• The participant must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For participants with prior radiation therapy, measurable lesions must be outside of any prior radiation field\[s\], unless disease progression has been documented at that disease site subsequent to radiation.)
• The participant is ≥18 years old.
• The participant has an Eastern Cooperative Oncology Group Performance Status of 0-2.
• The participant has adequate baseline organ function, as demonstrated by the following:
• Serum creatinine ≤1.5 × institutional upper limit of normal (ULN) or calculated creatinine clearance \>30 milliliters (mL)/minute.
• Serum albumin ≥2.5 grams/deciliter (g/dL).
• Bilirubin ≤1.5 × institutional ULN.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (participants with hepatic metastases must have AST/ALT ≤5 times ULN).
• International normalized ratio ≤1.5 or prothrombin time ≤1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (partial thromboplastin time or activated partial thromboplastin time) ≤1.5 × ULN.
• The participant has adequate baseline hematologic function, as demonstrated by the following:
• Absolute neutrophil count ≥1.5×10\^9/liter (L)
• Hemoglobin ≥8 g/dL, with no red blood cell transfusions within the prior 14 days.
• Platelet count ≥100×10\^9/L, with no platelet transfusions within the prior 14 days.

You may not qualify if:

• The participant has persistent clinically significant ≥Grade 2 toxicities from previous anticancer therapy (excluding Grade 2 chemotherapy-related neuropathy which is permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).
• The participant has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 28 days prior to study entry (Participants with advanced prostate cancer who are receiving luteinizing hormone releasing hormone \[LHRH\] agonists are permitted onto the study and should continue use of these agents during study treatment).
• The participant has received treatment with an investigational systemic anticancer agent within 28 days prior to C1D1.
• The participant has previously received treatment with SL-801 or another investigational agent that inhibits the XPO1/CRM1 pathway.
• The participant has an additional active malignancy that may confound the assessment of the study endpoints. Participants with a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Participants with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia), organ-confined prostate cancer with no evidence of progressive disease.
• The participant has clinically significant cardiovascular disease (for example, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
• The participant has uncontrolled, clinically significant pulmonary disease (for example, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the participant at significant risk for pulmonary complications during the study.
• The participant has known active or suspected brain or leptomeningeal metastases. (Central nervous system \[CNS\] imaging is not required prior to study entry unless there is a clinical suspicion of CNS involvement). Participants with stable, treated brain metastases are eligible provided there is no evidence of CNS disease growth on imaging for at least 3 months following radiation therapy or other locoregional ablative therapy to the CNS.
• The participant is receiving immunosuppressive therapy for prophylaxis following a prior organ transplant (solid organ or allogeneic stem cell) or management of immune-mediated toxicities due to immunotherapy. Low-dose corticosteroid (defined as \< 10 mg/day of prednisone or equivalent) therapy is permitted.
• The participant has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
• The participant is pregnant or breast feeding.
• The participant has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
• The participant is oxygen dependent.
• The participant has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities.

Sponsors & Collaborators

• Stemline Therapeutics, Inc.: lead

Study Sites (6)

Yale Cancer Center

New Haven, Connecticut, 06520, United States

Location

Florida Cancer Specialist

Sarasota, Florida, 34236, United States

Location

Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

Location

Mary Crowely Cancer Research Centers- Medical City

Dallas, Texas, 75230, United States

Location

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

Location

University of Washington, Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States

Location

Related Publications (24)

• Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med. 1998 Jul 30;17(14):1537-49. doi: 10.1002/(sici)1097-0258(19980730)17:143.0.co;2-f.

  PMID: 9699228 BACKGROUND

• Arnaoutov A, Azuma Y, Ribbeck K, Joseph J, Boyarchuk Y, Karpova T, McNally J, Dasso M. Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol. 2005 Jun;7(6):626-32. doi: 10.1038/ncb1263.

  PMID: 15908946 BACKGROUND

• Dillman RO, Koziol JA. Phase I cancer trials: limitations and implications. Mol Biother. 1992 Sep;4(3):117-21.

  PMID: 1445664 BACKGROUND

• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

  PMID: 19097774 BACKGROUND

• Gatsonis C, Greenhouse JB. Bayesian methods for phase I clinical trials. Stat Med. 1992 Jul;11(10):1377-89. doi: 10.1002/sim.4780111011.

  PMID: 1518998 BACKGROUND

• Gerecitano J. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents. J Hematol Oncol. 2014 Oct 4;7:67. doi: 10.1186/s13045-014-0067-3.

  PMID: 25281264 BACKGROUND

• Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med. 2009 Dec 1;32(6):E315.

  PMID: 20003838 BACKGROUND

• International Conference on Harmonisation. E8: General Considerations for Clinical Trials, July 1997.

  BACKGROUND

• Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16;121(20):4166-74. doi: 10.1182/blood-2012-08-447581. Epub 2013 Apr 5.

  PMID: 23564911 BACKGROUND

• Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012 Nov 29;120(23):4621-34. doi: 10.1182/blood-2012-05-429506. Epub 2012 Oct 3.

  PMID: 23034282 BACKGROUND

• Lassen UN, Mau-Soerensen M, Kung AL, Wen PY, Lee EQ, Plotkin SR, et al. A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). J Clin Oncol 33, 2015 (suppl; abstr 2044)

  BACKGROUND

• Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer. 2008 Apr 15;112(8):1733-43. doi: 10.1002/cncr.23354.

  PMID: 18306389 BACKGROUND

• Pathria G, Wagner C, Wagner SN. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol. 2012 Dec;132(12):2780-90. doi: 10.1038/jid.2012.233. Epub 2012 Jul 26.

  PMID: 22832492 BACKGROUND

• Saito N, Sakakibara K, Sato T, Friedman JM, Kufe DW, VonHoff DD, Kawabe T. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Mol Cancer Ther. 2014 Dec;13(12):3013-23. doi: 10.1158/1535-7163.MCT-14-0064. Epub 2014 Sep 24.

  PMID: 25253782 BACKGROUND

• Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, Kufe DW, Vonhoff DD, Iwami T, Kawabe T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 6;118(14):3922-31. doi: 10.1182/blood-2011-01-333138. Epub 2011 Aug 12.

  PMID: 21841164 BACKGROUND

• Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19.

  PMID: 24755012 BACKGROUND

• Siddiqui N, Borden KL. mRNA export and cancer. Wiley Interdiscip Rev RNA. 2012 Jan-Feb;3(1):13-25. doi: 10.1002/wrna.101. Epub 2011 Jul 27.

  PMID: 21796793 BACKGROUND

• Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989 Sep;45(3):925-37.

  PMID: 2790129 BACKGROUND

• Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov. 2014 May;4(5):527-37. doi: 10.1158/2159-8290.CD-13-1005. Epub 2014 Apr 17.

  PMID: 24743138 BACKGROUND

• Tan DSP, Pang M-Y, Yong WP, Soo RA, Chee CE, Thian YL et al. Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers. J Clin Oncol 33, 2015 (suppl; abstr 2542).

  BACKGROUND

• Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012 Apr 15;83(8):1021-32. doi: 10.1016/j.bcp.2011.12.016. Epub 2011 Dec 20.

  PMID: 22209898 BACKGROUND

• van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009 Apr 15;124(8):1829-40. doi: 10.1002/ijc.24146.

  PMID: 19117056 BACKGROUND

• Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

  PMID: 23970380 BACKGROUND

• Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 2005 Aug;7(8):823-30. doi: 10.1038/ncb1282. Epub 2005 Jul 24.

  PMID: 16041368 BACKGROUND

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 3, 2015
• First Posted: January 29, 2016
• Study Start: February 23, 2016
• Primary Completion: October 6, 2021
• Study Completion: October 13, 2021
• Last Updated: February 10, 2025

Record last verified: 2025-02

Locations

US (6)